Selective Factor XIa Inhibitors for Anticoagulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anticoagulants for treating thromboembolic disorders, such as warfarin, have limitations including a narrow therapeutic index, slow onset, dietary and drug interactions, and the need for monitoring, highlighting the need for safe and efficacious oral anticoagulants that can effectively inhibit thrombin generation.
Innovation Solution
Development of novel arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea compounds that act as selective inhibitors of serine protease enzymes like factor XIa and/or plasma kallikrein, which are used in pharmaceutical compositions for the treatment or prophylaxis of thromboembolic disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If warfarin is used as an anticoagulant, then thrombin generation is inhibited, but the therapeutic index is narrow and monitoring is required
Solution Approach 1:
The patent extracts and targets a specific enzyme (factor XIa) in the coagulation cascade pathway, rather than using broad-spectrum anticoagulants like warfarin. This selective inhibition approach isolates the therapeutic action to a single critical step in thrombin generation, eliminating the need for monitoring while maintaining efficacy.
Solution Approach 2:
The invention changes the pharmacological parameter from non-selective vitamin K antagonism to selective factor XIa inhibition. This parameter change in mechanism of action provides a narrower therapeutic window with predictable efficacy, eliminating the narrow therapeutic index problem of warfarin without requiring monitoring.
2Reliability
If warfarin is used as an anticoagulant, then thrombin generation is inhibited, but dietary and drug interactions occur
Solution Approach 1:
The patent extracts and targets a specific enzyme (factor XIa) in the coagulation cascade pathway, rather than using broad-spectrum anticoagulants like warfarin. This selective inhibition approach isolates the therapeutic action to a single critical step in thrombin generation, eliminating the need for monitoring while maintaining efficacy.
3Reliability
If factor XIa is selectively inhibited, then thrombin generation is reduced, but selectivity versus other proteases must be maintained
Solution Approach 1:
The patent applies local quality by designing compounds with specific structural features (arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea moieties) that are tailored to fit the factor XIa active site. This localized molecular design ensures high affinity and selectivity for factor XIa while minimizing interaction with other proteases in the coagulation cascade.
Solution Approach 2:
The invention uses a carefully designed small molecule compound as an intermediary that specifically binds to factor XIa. This intermediary molecule acts as a selective bridge between the therapeutic goal (inhibiting thrombin generation) and the molecular target (factor XIa active site), ensuring specificity while avoiding off-target effects on other proteases.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds provide effective inhibition of factor XIa and plasma kallikrein, potentially offering a safer and more efficient alternative to existing anticoagulants by reducing the risk of thromboembolic events with improved pharmacokinetic properties and reduced adverse effects.
Implementation Method 1
novel arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea compounds, and analogues thereof, which are useful as selective inhibitors of serine protease enzymes, especially factor XIa and/or plasma kallikrein
Data Source
AI summary
The present invention provides compounds of Formula (I) or (II): or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, L1, R3, R4, R8a, R11 and M are as defined herein. The compounds of Formula (I) or (II) are selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; for example thrombin, factor Xa, factor XIa, factor IXa, factor VIIa and/or plasma kallikrein. In particular, it relates to compounds that are selective factor XIa inhibitors or dual inhibitors of fXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.